Loading clinical trials...

Clinical Efficacy of Exoskeleton Robot-Assisted Rehabilitation on Lower Limb Functional Recovery in Elderly Patients With Hip Fracture | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATIONNA

Clinical Efficacy of Exoskeleton Robot-Assisted Rehabilitation on Lower Limb Functional Recovery in Elderly Patients With Hip Fracture

Clinical Efficacy of Exoskeleton Robot-Assisted Rehabilitation on Lower Limb Functional Recovery in Elderly Patients With Hip Fracture: A Multicenter, Open-Label, Randomized Controlled Clinical Trial

NCT07323147•Hai bao

View on ClinicalTrials.gov

Summary

With the intensification of population aging, hip fracture, as a common bone disease, is seeing an increasing incidence rate among the elderly population. Traditional rehabilitation training methods can no longer fully meet the functional recovery needs of elderly patients with hip fractures. Due to their wearability and intelligence, exoskeleton robots provide an innovative solution for rehabilitation training. This study aims to explore the application effects of exoskeleton robots in postoperative rehabilitation for elderly patients with hip fractures by utilizing exoskeleton robot-assisted rehabilitation training for elderly hip surgery patients. The focus is on its improvements in motor ability, balance ability, and pain levels, while also assessing its impact on patients' overall quality of life and the prevention of complications.

Eligibility

Age

65 - 100 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 65 years or older, regardless of gender.
•Diagnosed with a unilateral hip fracture resulting from low-energy trauma by imaging (X-ray/CT), and having undergone surgical treatment (internal fixation or arthroplasty).
•The participant or their legal guardian understands and agrees to participate in the clinical trial and is willing to provide voluntary written informed consent.

Exclusion Criteria

•Life expectancy of less than 6 months.
•History of neurological disorders such as prior stroke, spinal cord injury, Parkinson's disease, or myasthenia gravis.
•Severe joint contractures, deformities, or heterotopic ossification in the lower limbs that would prevent proper device fitting.
•Body weight exceeding the device's maximum load capacity (\>100 kg).
•Height outside the adjustable range of the device.
•Presence of a pathological fracture or multiple fragility fractures.
•Presence of severe osteoarthritis or trauma in the contralateral lower limb that significantly impairs function.
•Comorbidities including active malignancy or systemic infection.
•Comorbidities such as thromboembolic disease in the lower limbs, pneumonia, or pressure injuries (bedsores).
•Comorbidities affecting rehabilitation capacity, including unstable angina, heart failure, severe sequelae of stroke, severe chronic obstructive pulmonary disease (COPD), or severe hepatic/renal dysfunction.
+2 more criteria

Locations (1)

Beijing Jishuitan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Key Dates

Start Date

February 1, 2026

Primary Completion Date

May 1, 2026

Completion Date

December 30, 2026

Last Updated

January 23, 2026

Enrollment

ESTIMATED participants

Conditions

Hip FractureGeriatricsLower Extremity DysfunctionPostoperative RehabilitationGait Disorders

Interventions

Exoskeleton

DEVICE

Conventional rehabilitation program

OTHER

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

NCT06565910

Femoral Neck FracturesFemur Head Necrosis+1 more

View study

RECRUITINGNA

Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia

NCT07442721

Hip ArthroplastyHip Fracture Surgeries+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Clinical Efficacy of Exoskeleton Robot-Assisted Rehabilitation on Lower Limb Functional Recovery in Elderly Patients With Hip Fracture

Inclusion Criteria

Exclusion Criteria

Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)

Sacral ESPB vs. PENG Block for Hip Hemiarthroplasty Analgesia

One Versus Two Doses of Tranexamic Acid in Surgically Treated Extracapsular Hip Fractures

Strength-based Tailored-Exercise Program at Home for Geriatric Patients

Evaluation of Fracture Migration After Internal Fixation of Femoral Neck Fractures in Younger Adults: A Clinical RCT Using RSA

Comparison of Cryoablation of Pericapsular Nerve Group (PENG) to Fascia Iliaca Catheter in Patients With a Hip Fracture